Tiziana Life Sciences Announces Results Of PET Scan Showing Marked Reduction In Microglia Activation Associated With Neuroinflammation In AD Patient Treated With Intranasal Foralumab

Author: Benzinga Newsdesk | May 09, 2025 07:04am

Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced results of a PET scan showing a marked reduction in microglia activation associated with neuroinflammation in a patient suffering from moderate Alzheimer's disease (AD) who was treated for three months with intranasal foralumab under an expanded access program. The microglial TSPO PET scan revealed a significant decrease in microglia activation, a key indicator of neuroinflammation associated with Alzheimer's disease progression.

Posted In: TLSA